Delcath Systems Announces Positive Independent Study Results for Liver-Directed Therapy in Uveal Melanoma

DELCATH SYSTEMS, INC.

Study of 167 patients showed median melanoma-specific survival of 28 months with first-line liver-directed therapy vs 10 months with systemic therapy.
Patients diagnosed 2016-2021 receiving liver-directed therapy had median MSS of 30 months, compared to 20 months for 2005-2015 cohort.
CHEMOSAT Hepatic Delivery System was used in the study; 30 of 56 patients in 2016-2021 period received CHEMOSAT.
Study published in Therapeutic Advances in Medical Oncology, conducted by University of Tübingen researchers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.